Top 20 Biologics 2007 RD Pipeline News

March 27, 2008 | Special Edition 1
TOP 20 Biologics 2007
March 27, 2008
March 27, 2008

Special Edition 1
TOP 20 Biologics 2007 Features:
• TOP 20 Blockbuster Drugs 2007
• TOP 13 Biologics Classes 2007
• Blockbuster Biologics 2007 by Class
• Selected Other Recombinant Biologics
• Selected Other Non-Recombinant Biologics

1/20
La Merie S.L. | Email info@lamerie.com | Internet www.lamerie.com
Subscribe now!
TOP 20 Biologics in 2007
ID Product Target / Class of Company Product Indication 2007 sales (vs 2006)
No. Name Mechanism Compound Category
of Action
1 epoetin alfa; EPO-R Rhu protein Amgen & Kirin Protein Renal and US$ 5,764 mln (US$ 6,024)
Epogen / & Johnson & cancer anemia
ESPO / Johnson
Procrit /
Eprex
2 etanercept; TNF-alpha Rec fusion Amgen & Antibody Rheumatoid US$ 5,453 mln (US$ 4,474)
Enbrel / protein of Fc Wyeth & arthritis;
Embrel + sol TNF-R Takeda psoriasis etc
3 rituximab; CD20 Rec chimeric Genentech/ Antibody 1st line treat- US$ 5,392 mln (US$ 3,912)
Rituxan / mab Roche /Chugai ment of diffuse,
MabThera Biogen IDEC, large B-cell,
Zenyaku CD20+ NHL plus
Kogyu chemotherapy
4 trastuzumab HER2 Rec huma- Roche / Antibody Metastatic US$ 4,743 mln (US$ 3,175)
Herceptin nized mab Genentech breast cancer
5 infliximab TNF-alpha Rec chimeric Centocor (J&J) Antibody Rheumatoid US$ 4,465 mln (US$ 3,764)
Remicade; mab & Schering- arthritis etc
Plough & Tan-
abe Seiyaku
6 bevacizumab VEGF Rec Roche & Antibody Metastatic US$ 4,014 mln (US$ 2,395)
Avastin humanized Genentech colorectal cancer
mab
7 darbepoetin EPO-R Rhu glycol- Amgen & Kirin Protein Renal and US$ 4,004 mln (US$ 4,121)
Aranesp / engineered Pharma cancer anemia
NESP protein
8 insulin Insulin Rhu insulin Sanofi-Aventis Protein Diabetes US$ 3,167 mln (US$ 2,188)
analog receptor analog mellitus
glargine ;
Lantus
9 adalimumab; TNF-alpha Rec fully Abbott Antibody Rheumatoid US$ 3,064 mln (US$ 2,044)
Humira human mab (& Eisai) arthritis,
psoriasis etc
2/20
of Action
10 Neulasta; G-CSF- Pegylated Amgen Protein Neutropenia US$ 3,000 mln (US$ 2,710)
peg- receptor rhu protein
filgrastim
11 insulin Insulin Rhu insulin Novo Nordisk Protein Diabetes US$ 2,929 mln (US$ 1,908)
analogs receptor analogues
aspart /
determir;
Levemir;
NovoLog
(Mix)
12 Human Insulin Rhu proteins NovoNordisk Protein Diabetes US$ 2,629 mln (US$ 2,653)
insulin; receptor
Actrapid /
Novolin;
Insulatard;
Mixtard
13 epoetin EPO-R Rhu protein Roche & Protein Renal and US$ 2,047 mln (US$ 1,794)
beta; Chugai cancer anemia
Neo-
recormon /
Epogin
14 interferon IFN-R Rhu protein Merck Serono Protein Multiple sclerosis US$ 1,875 mln (US$ 1,804)
beta-1a
Rebif
15 inteferon IFN-R Rhu protein Biogen Idec Protein Multiple sclerosis US$ 1,868 mln (US$ 1,707)
beta-1a;
Avonex
16 interferon IFN-R Rhu protein Bayer Schering Protein Multiple sclerosis US$ 1,603 mln (US$ 1,545)
beta-1b; Pharma
Betaferon /
Betaseron;
3/20
of Action
17 peginterfer- IFN-R Pegylated Roche Protein Hepatitis B and US$ 1,600 mln (US$ 1,186)
on alfa-2a; rec hu C
Pegasys protein
18 Insulin Insulin Rhu insulin Eli Lilly Protein Diabetes US$ 1,475 mln (US$ 1,300)
analog lispro receptor analog
Humalog
19 filgrastim G-CSF- Rhu protein Amgen & Kirin Protein Neutropenia US$ 1,419 mln (US$ 1,344)
Neupogen / receptor
GRAN
20 cetuximab EGF-R Rec chimeric Bristol-Myers Antibody Refractory meta- US$ 1,416 mln (US$ 1,095)
Erbitux mab Squibb & static colorectal
Merck Serono cancer;
(from Head & neck
ImClone) cancer
4/20
No. Previous Class of Products 2007 sales Change vs Selected Branded Products
Year
(US$ bln.) 2006
1 2 Major cancer antibodies 15.74 + 48 % Rituxan/MabThera, Herceptin, Avastin,
Erbitux, Vectibix
2 3 Anti-TNF antibodies 12.98 + 26.3 % Enbrel, Remicade, Humira
3 1 Erythropoietins 11.82 -1% Aranesp, Procrit Eprex, Epogen, Neo-

Recormon, ESPO
4 4 Insulin and insulin analogs 11.19 + 24.7 % Humalog, Humulin, Lantus, Levemir,
Novorapid, Actrapid, Novolin
5 5 Rec. coagulation factors 5.39 + 14.4 % Novoseven, Kogenate, Helixate, Refacto,
Advate, Recombinate, Benefix
6 6 Interferon beta 5.35 + 21.5 % Avonex, Rebif, Betaferon / Betaseron
7 7 G-CSF 4.82 + 10.4 % Neulasta, Neupogen, Neutrogin, GRAN
8 8 Human growth hormone 2.77 + 12.1 % Genotropin, Norditropin, Humatrope,

Nutropin, Saizen, Serostim
9 9 Interferon alpha 2.74 + 21.4 % Pegasys, Peg-Intron, Intron A
10 10 Enzyme Replacement 2.29 + 34.1 % Cerezyme, Fabrazyme, Aldurazyme,

Myozyme, Replagal, Naglazyme, Elaprase
11 - Ophthalmic antibody 1.36 - Lucentis
12 12 Follicel stimulating hormone ~ 1.28 + 21.8 % Gonal-f, Puregon/Follistim
13 11 Antiviral antibody > 1.13 + 2.3 % Synagis
Total: 78.86 + 15 %
5/20
Product Type: Pharmaceutical Category: Cancer antibodies - No. 1
ID Product Target / Class of Company Product Indication 1st 2007 sales (mln)
No. Name Mechanism Compound Category appr vs. previous year (%)
of Action oval
Rituxan / CD20 Rec chimeric Genentech/ Antibody 1st line treat- 1997 CHF 5,516 (+ 15 %)
MabThera; mab Roche /Chugai ment of diffuse, = US$ 5,392* source
rituximab Biogen IDEC large B-cell,
Zenyaku CD20+ NHL plus
Kogyu chemotherapy
Herceptin, HER2 Rec Roche / Antibody Metastatic CHF 4,852 (+ 23 %)
trastuzumab humanized Genentech breast cancer = US$ 4,743* source
mab
Avastin; VEGF Rec Roche / Antibody Metastatic CHF 4,106 (+ 41)
bevacizumab humanized Genentech colorectal cancer = US$ 4,014* source
mab
Erbitux; EGF-R Rec chimeric Bristol-Myers Antibody Refractory BMS = US: US$ 692 (+ 6 %)
cetuximab mab Squibb & metastatic source
Merck Serono colorectal Merck Serono = Non-US: € 470
(from cancer; mln (+ 40 %) = US$ 724 source
ImClone) Head & neck
cancer total Erbitux sales: US$ 1,416
Vectibix; EGF-R Rec fully Amgen Antibody 3rd line 2006 US$ 170 (+ 336 %) source
panitumu- human mab metastatic
mab colorectal cancer
Total: US$ 15,735

* strong influence of currency exchange rate (CHF into US$)
6/20
6
Product Type: Pharmaceutical Category: Anti-TNF Biologics– No. 2
of Action oval
Enbrel; TNF-alpha Fusion Amgen Fusion Rheumatoid North America: US$ 3,230 (+ 12
etanercept protein of Fc protein arthritis; %) source
+ sol TNF-R psoriasis etc
Enbrel; TNF-alpha Fusion Wyeth Fusion Rheumatoid Ex-US and Canada: US$ 2,045 (+
etanercept protein of Fc (from Amgen) protein arthritis; 36 %) source
+ sol TNF-R psoriasis etc
Embrel; TNF-alpha Fusion Takeda Phar- Fusion Rheumatoid 03/ Q2-4: Y 14.3 bln source
etanercept protein of Fc maceuticals protein arthritis 2005 Extrapolated Q1-4: Yen 19 bln (+
+ sol TNF-R (from Wyeth) 66.5 %) = US$ 177.6
Co-promotion with Wyeth KK
Remicade; TNF-alpha Rec chimeric Centocor / J&J Antibody Rheumatoid Exclusive US$ = 2,534 (+ 7.6 %)
infliximab mab arthritis etc + Intl to partners (793: + 20.5 %)
(10 indications) Total: US$ 3,327 source
Remicade; TNF-alpha Rec chimeric Tanabe Antibody Rheumatoid Forecast fiscal year 2007:
infliximab mab Seiyaku arthritis; Yen 28.3 bln (+ 38 %)
(from psoriasis etc = US$ 283 source for Japan and
Centocor) certain Asian countries
Remicade; TNF-alpha Rec chimeric Schering- Antibody Rheumatoid US$ 1,648 (+ 33 %*) source
infliximab mab Plough arthritis; For non-US territory = RoW except
psoriasis etc US, Japan and certain Asian
countries (Tanabe territories)
Humira TNF-alpha Rec fully Abbott Antibody Rheumatoid US$ 3,064 (+ 49.9 %) source
adalimumab human mab (& Eisai) arthritis, Approved in six indications
psoriasis etc
Total: US$ 12,982
7/20
Product Type: Pharmaceutical Category: EPOs – No. 3
5 of Action oval
Aranesp; EPO-receptor Glyco- Amgen Protein Renal and US$ 3,614 (- 12 %) source
darbepoetin engineered cancer anemia
rhu protein
NESP; EPO-R Glyco- Kirin Pharma Protein Anemia 07/ Combined sales of ESPO + NESP:
darbepoetin; engineered (from Amgen) 2007 Yen 41.7 bln (+ 0.3 %) = US$ 390
KRN321 rhu protein mln source
Procrit / EPO-R Rhu protein Johnson & Protein Renal and US$ 2,885 (- 12 %) source
Eprex; Johnson cancer anemia
epoetin alfa (from Amgen)
Epogen; EPO-R Rhu protein Amgen Protein Renal and US$ 2,489 (- 1 %) source
epoetin alfa cancer anemia
ESPO; EPO-R Rhu protein Kirin Pharma Protein Anemia Combined sales of ESPO + NESP:
epoetin alfa (from Amgen) Yen 41.7 bln (+ 0.3 %) = US$ 390
mln source > 50 % market share
Neo- EPO-R Rhu protein Roche & Protein Renal and NeoRecormon: CHF 1,536 (- 4 %)
recormon / Chugai cancer anemia = US$ 1501
Epogin; Epogin: CHF 558 (- 14 %) = US$
epoetin beta 545
Combined epoetin beta sales:
CHF 2,094 (- 7 %) = US$ 2,047
source
Total: US$ 11,815
8/20
Product Type: Pharmaceutical Category: Insulin products – No. 4
of Action oval
Humalog; Insulin Rhu insulin Eli Lilly Protein Diabetes US$ 1,475 (+ 13 %) source
insulin lispro receptor analog
Humulin Insulin Rhu insulin Eli Lilly Protein Diabetes US$ 985 (+ 6 %) source
receptor
Lantus; Insulin Rhu insulin Sanofi-Aventis Protein Diabetes € 2,031 (+ 21.9 %)
insulin receptor analog once mellitus = US$ 3,167 source
glargine daily
Levemir Insulin Rhu (basal) Novo Nordisk Protein Diabetes Combined sales of Novo’s insulin
receptor insulin analogs: DKK 14,008 (+ 29 %)
analogue = US$ 2,929 source
detemir
NovoLog Insulin Rhu rapid Novo Nordisk Protein Diabetes
(Mix) receptor acting insulin
analogue
aspart
Actrapid / Insulin Rhu insulin Novo Nordisk Protein Diabetes Human insulins: DKK 12,572 (- 7
Novolin; receptor and related %) = US$ 2,629 source
Insulatard; products
Mixtard
Total: US$ 11,185
9/20
8
Product Type: Pharmaceutical Category: Rec. coagulation factors – No 5
No. Name Mechanism Compound Category appr vs. previous year
of Action oval
NovoSeven; Coagulation Rhu factor Novo Nordisk Protein Hemophilia DKK 5,865 (+ 4 %) = US$ 1,226
eptacog alfa factor VIIa source
replacement
Kogenate FS Coagulation Rhu factor Bayer Schering Protein Hemophilia A € 818 ( + 3.9 %) = US$ 1,276
+ BioSet; factor VIII + need- Pharma source
octocog replacement le-free inject
Helixate FS Factor VIII Rhu factor CSL Behring Cardio- Hemophilia A Fully year 2006/7: 17 % of AUS$
substitution VIII formul. (from Bayer vascular & 2.6 bln (442) = US$ 403 mln
with sucrose Schering) blood source (H2/2007 = AUS$ 228 =
US$ 208 source )
Advate; Factor VIII Plasma + Baxter Cardio- Hemophilia A 2007 sales > US$ 1,200 source
rAHF substitution albumin free vascular &
processed blood
rhu protein
Recombinate Factor VIII Rhu factor Baxter Cardio- Hemophilia A Combined 2007 sales of
rAHF substitution VIII (from vascular & Recombinate and Advate = US$
GI/Wyeth) blood 1,714 mln (+ 13 %) source
Refacto Coagulation Rhu B-dom- Wyeth Protein Hemophilia A US$ 335 (+ 9.6 %) source
factor ain deleted
replacement factor VIII
Benefix; Coagulation Rhu factor IX Wyeth Protein Hemophilia B US$ 433 (+ 21 %) source
Nonacog alfa factor transition of rights to Wyeth since
reformulated replacement July 2007 in EMEA states
BeneFIX; Substitution Rec human Baxter Cardio- Hemophilia B < US$ 43 (all hospital distributed
Nonacog alfa of factor IX factor IX (exclusive in vascular & products incl. BeneFIX)
reformulated reformulated Europe) blood - not considered -
Total: US$ 5,387
10/20
Product Type: Pharmaceutical Category: Interferon beta – No- 6
of Action oval
Avonex; IFN-R Rhu Biogen Idec Protein Multiple sclerosis US$ 1,868 (+ 9 %) source
inteferon interferon β-
beta-1a 1a
Rebif; IFN-R Rhu Merck Serono Protein Multiple sclerosis EURO 1,218 (+ 5.3 %)= US$
interferon interferon β- & Pfizer 1,875 source reporting of Merck
beta-1a 1a Serono includes Pfizer sales source
Betaferon / IFN-R Rhu Bayer Schering Protein Multiple sclerosis € 1,028 (+ 3.7 % pro forma) =
Betaseron; interferon β- Pharma US$ 1,603 source
interferon 1b
beta-1b
Total: US$ 5,346
11/20
Product Type: Category: G-CSF – No. 7

Pharmaceutical
of Action oval
Neulasta; G-CSF- Pegylated Amgen Protein Neutropenia US$ 3,000 (+ 10.7 %) source
peg- receptor rhu protein associated with
filgrastim chemotherapy
Neupogen / G-CSF- Rhu protein Amgen Protein Neutropenia Amgen: US$ 1,277 (+5.3 %)
GRAN; receptor associated with source
filgrastim chemotherapy Kirin: Yen 15.2 bln (- 1 %) = US$
142 mln source
Total: US$ 1,419 mln
Neutrogin; G-CSF- Rhu protein Chugai Protein Neutropenia CHF 405 (+ 13%)
lenograstim receptor (Roche) associated with = US$ 396
chemotherapy source
Total: > US$ 4,815
12/20
11
Product Type: Pharmaceutical Category: human Growth Hormone – No. 8
of Action oval
Genotropin Regulation of Rec human Pfizer Protein Growth hormone US$ 843 (+ 6 %) source
postnatal protein deficiency
growth
Norditropin Regulation of Rec human Novo Nordisk Protein Growth hormone DKK 3,511 (+ 6 %)
postnatal protein deficiency = US$ 734 source
growth
Humatrope; Regulation of Rec human Eli Lilly Protein Growth hormone Estimate of US$ 441 (+ 6 % )
postnatal protein deficiency source
growth
Nutropin; Regulation of Rec human Genentech Protein Growth hormone CHF 470 (- 1) = US$ 459
Protropin; postnatal protein (Roche) deficiency source
somatropin; growth
somatrem
Nutropin AQ Regulation of Rec human Ipsen Protein Growth hormone € 23.7 (+ 61 %) = US$ 37
Pen; postnatal protein (from Genen- deficiency source License for RoW except
somatropin growth tech / Roche) North America and Japan
Saizen / Regulation of Rec human Merck Serono Protein Growth hormone Saizen: EURO 163.1 (- 2 %) = US$
Serostim postnatal protein deficiency 254 source
growth
Total: US$ 2,768
13/20
1
Product Type: Pharmaceutical Category: Interferon alfa – No. 9
Product Target / Class of Company Product Indication 1st 2007 sales (mln)
Name Mechanism Compound Category appr vs. previous year (%)
of Action oval
Pegasys; IFN-R Pegylated Roche Protein Hepatitis B and CHF 1,637 (+ 11 %)
peginterfer- rec hu C = US$ 1,600 source
on alfa-2a protein
Peg-Intron; IFN-R Pegylated Schering- Protein Hepatitis C US$ 911 (+ 9 %) source
pegylated rhu protein Plough
IFN alfa-2b
Intron A; IFN-R Rhu protein Schering- Protein Hepatitis US$ 233 (- 2 %) source
interferon Plough
alfa-2b
Total: US$ 2,744
1 14/20
Product Type: Pharmaceutical Category: Enzyme Replacement – No. 10
Name Mechanism Compound Category appr vs. previous year
of Action oval
Cerezyme; Beta-gluco- Imiglucerase Genzyme Protein Gaucher’s US$ 1,133 (+ 12.5 %) source
imiglucerase cerebrosidase for injection disease
replacement
Fabrazyme; Alpha Rhu enzyme Genzyme Protein Fabry disease US$ 424 (+ 18.1 %) source
agalsidase galactosidse A
beta replacement
Myozyme; Acid-alpha- Rhu enzyme Genzyme Protein Pompé disease US$ 201 (+ 239 % ) source
alglucosidase glucosidase
alfa replacement
Aldurazyme; Alpha-L- Rhu enzyme Genzyme & Protein Hurler and US$ 123.7 (+ 28.5 %) source
laronidase iduronidase BioMarin Hurler-Scheie Total product sales of Joint Venture
replacement forms of
mucopoly-
saccharidosis I
(MPS I)
Elaprase; Iduronate-2- Rhu enzyme Shire Protein Hunter 2006 US$ 181.8 (+ 670 %) source
idursulfase sulfatase (from TKT) syndrome
replacement (MPS II)
Replagal; Alpha- Rhu enzyme Shire & Protein Fabry disease US$ 143.9 (+ 22 %) source
agalsidase galactosidase Dainippon In Japan approved in Oct 2007
alfa replacement Sumitomo
Naglazyme; N-acetyl- Rhu enzyme BioMarin Protein MPS VI US$ 86.2 (+ 85.4 %) source
galsulfase galactosamine
4-sulfatase
replacement
Total: US$ 2,293.6
15/20
Product Type: Pharmaceutical Category: Ophthalmic antibody - 11
of Action oval
Lucentis; VEGF Rec Genentech Antibody Wet age-related 2006 Genentech for US: CHF 991 = US$
ranibizumab humanized (Roche) & macular US; 969 (+ 117 %) source
Fab Novartis degeneration 2007 Novartis for ex-US: US$ 393 source
EU Total : US$ 1,362
Product Type: Pharmaceutical Category: Follicle stimulating hormones – No. 12
of Action oval
Gonal-f; FSH-R Rhu protein Merck Serono Protein Infertility EURO 434.2 (+ 2 %) = US$ 668
follitropin source
alfa
Puregon; FSH-R Rhu protein Schering- Protein Infertility US$ 57 mln (from Nov 19 to Dec
Follistim Plough 31, 2007) source
follitropin (ex Organon) 2006 sales: € 384 (+ 8 %) = US$
beta 599 source
Approximately Total: US$ 1,267
Product Type: Pharmaceutical Category: Antiviral antibody – No. 13
of Action oval
Synagis, Respiratory Rec huma- AstraZeneca Antibody Prevention of 1999 Jan – March 2007: US$ 507 source
palivizumab syncytical nized mab (MedImmune) RSV in pre- June – Dec 2007: US$ 618 source
virus mature infants Total 2007 sales > US$ 1,125
16/20
Product Type: Pharmaceutical Category: Selected Other Recombinant Biologics
of Action oval
Forteo; PTH-R Rhu peptide Eli Lilly Peptide Osteoporosis US$ 709 (+ 19 %) source
teriparatide (PTH 1-34)
Preotact PTH-R Rhu peptide Nycomed Peptide Osteoporosis 2006 € 18 mln (+ 2,395 %) = US$ 28
(EU) / (PTH 1-84) (from NPS source
Preos (US) Pharma-
ceuticals)
Raptiva; CD11a Rec Genentech Antibody Mild to moderate Roche: CHF 144 (+ 15 %) = US$
efalizumab humanized (Roche) & psoriasis 141 source
mab Merck Serono Ex-US : EURO 76.3 (+ 37 %) =
US$ 117 source
Total: US$ 258
Pulmozyme; DNA Rhu protein Genentech Protein Cystic fibrosis CHF 483 (+ 12 %) = US$ 472
dornase alfa (Roche) source
Orencia; CD80/CD86 Rec fusion Bristol-Myers Fusion Rheumatoid 2005 US$ 231 (+ 216 %) source
abatacept (B7.1 + B7.2) protein of Squibb protein arthritis
CTLA4 + Fc
Xolair; IgE Rec Genentech Antibody Asthma Roche: CHF 567 (+ 10 %) = US$
omalizumab humanized (Roche) & 554 source
mab Novartis Novartis: US$ 140 (+ 30 %) source
Combined : US$ 694
BMP-2; Tissue Rhu growth Wyeth Protein Spinal fusion + US$ 359 (+ 16.5 %), mainly in US
rhBMP2; regeneration factor long bone fusion source
InductOs
Activase / Plasminogen Rec hu Genentech Protein Acute Genentech: CHF 382 (+ 9 %) =
Alteplase; protein or (Roche) & myocardial US$ 373 source
Metalyse / rhu mutant Boehringer infarction; Boehringer Ingelheim 2006 sales of
TNKase; protein Ingelheim ischemic stroke both proteins: EURO 159 source in
tenecteplase H1/2007 – 11 %
17/20
Product Type: Pharmaceutical Category: Selected Other Recombinant Biologics
of Action oval
Tysabri; Alpha4 Rec Biogen Idec & Antibody Multiple Biogen Idec: US$ 230 source
natalizumab integrin humanized Elan sclerosis; Elan: US$ 343 source
mab Crohn’s disease
Xigris; Activated Rhu protein Lilly Protein High risk severe US$ 182.8 (- 5 %)
Drotrecogin protein C sepsis source
alfa
Actemra; Interleukin-6 Rec Roche Antibody Rheumatoid CHF 5 = US$ 5 (+ 21 %) source
tocilizumab receptor humanized (Chugai) arthritis
mab
18/20
Product Type: Pharmaceutical Category: Selected Other Non-recombinant Biologics
of Action oval
Copaxone; Immuno- Peptide Sanofi-Aventis Peptide Multiple sclerosis 1997 (Sanofi-Aventis: EURO 1,177 (+
Glatiramer modulator & Teva 10.1 %) source )
acetate Teva: global sales: US$ 1,713 (+
21 %) source
Botox; Neuro- Botulinum Allergan & Peptide Aesthetic and Allergan: US$ 1,212 mln (+23.4
botulinum muscular neurotoxin GSK (Japan medical %) source ;
toxin type A blockade type A and China) indications Allergan receives royalties from
GSK not included in sales figure
Dysport Neuro- Botulinum Medicis Peptide Aesthetic 2007 sales of € 128.7 mln (+ 13.6
(EU); muscular neurotoxin (NA + J) & medicine %) source
Reloxin blockade type A Galderma (EU) indications
(US);
botulinum (from Ipsen)
toxin type A
Byetta; GLP-1 GLP-1 analog Eli Lilly & Peptide Diabetes 2005 US$ 650 (+ 48 %) source
exenatide receptor Amylin Phar-
maceuticals
Fuzeon, HIV entry Linear 36-aa Roche & Peptide HIV CHF 320 (+ 3 %) = US$ 313
enfuvirtide inhibitor synthetic Trimeris source
peptide
Integrilin GP IIb/IIIa Peptide Schering- Peptide Acute coronary US$ 332 (+ 1 %) source
Plough syndrome
ReoPro; GP IIb/IIIa Peptide Lilly Peptide Acute coronary US$ 270.3 (- 4 %) source
abciximab syndrome
19/20
Learn more about R&D Pipeline News Why should you use R&D Pipeline
N ?
R&D Pipeline News is your weekly tool for • To keep up-to-date.
biopharmaceutical R&D analysis and it's available by annual
subscription. Examine the who, what, when, where of biotechnology R&D.
R&D Pipeline News will keep you up-to-date with the • To benchmark your company against the
latest R&D projects of the biopharmaceutical industry, with
competition
all the relevant treatment modalities and with competitive
information about ongoing R&D projects for a given Target,
Technology or Company. Keep en eye on your competitors’ projects and
developments, in which stage they are, their achievements,
handicaps, etc…and find out where you are standing in the
The R&D information is presented in an easy- and rapid-to-
market.
screen tabular format and grouped either in Therapeutic
Areas or Product Categories, saving you time in your
• To save time in your research
research.
Get the crucial information, in a one-shot tabular screen
grouped in Therapeutic Areas or Product Categories, and
deepen easily in those articles in which you are interested
Where can I get a subscription? with just one-click.
• To identify new business enterprises

Just visit our Online Store at www.pipelinereview.com
Recognize new business opportunities: joint ventures,
Or contact us at sales@lamerie.com licensing partners, co-marketing partners, etc..
• To receive news right in time
Get your personal copy every monday delivered by e-mail.
20/20

Top 20 Biologics 2007 RD Pipeline News

Hochgeladen von

Dokumentinformationen

Originalbeschreibung:

Copyright

Verfügbare Formate

Dieses Dokument teilen

Dokument teilen oder einbetten

Freigabeoptionen

Stufen Sie dieses Dokument als nützlich ein?

Sind diese Inhalte unangemessen?

Copyright:

Verfügbare Formate

Top 20 Biologics 2007 RD Pipeline News

Hochgeladen von

Copyright:

Verfügbare Formate

March 27, 2008 | Special Edition 1

TOP 20 Biologics 2007

March 27, 2008

March 27, 2008

TOP 20 Biologics 2007 Features:

• TOP 20 Blockbuster Drugs 2007

• TOP 13 Biologics Classes 2007

• Blockbuster Biologics 2007 by Class

• Selected Other Recombinant Biologics

• Selected Other Non-Recombinant Biologics

TOP 20 Biologics in 2007

TOP 20 Biologics in 2007

TOP 20 Biologics in 2007

2 3 Anti-TNF antibodies 12.98 + 26.3 % Enbrel, Remicade, Humira

3 1 Erythropoietins 11.82 -1% Aranesp, Procrit Eprex, Epogen, Neo-

7 7 G-CSF 4.82 + 10.4 % Neulasta, Neupogen, Neutrogin, GRAN

8 8 Human growth hormone 2.77 + 12.1 % Genotropin, Norditropin, Humatrope,

10 10 Enzyme Replacement 2.29 + 34.1 % Cerezyme, Fabrazyme, Aldurazyme,

12 12 Follicel stimulating hormone ~ 1.28 + 21.8 % Gonal-f, Puregon/Follistim

13 11 Antiviral antibody > 1.13 + 2.3 % Synagis

Product Type: Pharmaceutical Category: Cancer antibodies - No. 1

Total: US$ 15,735

Product Type: Pharmaceutical Category: Anti-TNF Biologics– No. 2

Total: US$ 12,982

Product Type: Pharmaceutical Category: EPOs – No. 3

Total: US$ 11,815

Product Type: Pharmaceutical Category: Insulin products – No. 4

Total: US$ 11,185

Product Type: Pharmaceutical Category: Rec. coagulation factors – No 5

Total: US$ 5,387

Product Type: Pharmaceutical Category: Interferon beta – No- 6

Total: US$ 5,346

Product Type: Category: G-CSF – No. 7

Total: > US$ 4,815

Product Type: Pharmaceutical Category: human Growth Hormone – No. 8

Total: US$ 2,768

Product Type: Pharmaceutical Category: Interferon alfa – No. 9

Total: US$ 2,744

Product Type: Pharmaceutical Category: Enzyme Replacement – No. 10

Total: US$ 2,293.6

Product Type: Pharmaceutical Category: Ophthalmic antibody - 11

Product Type: Pharmaceutical Category: Follicle stimulating hormones – No. 12

Approximately Total: US$ 1,267

Product Type: Pharmaceutical Category: Antiviral antibody – No. 13

Product Type: Pharmaceutical Category: Selected Other Recombinant Biologics

Product Type: Pharmaceutical Category: Selected Other Recombinant Biologics

Product Type: Pharmaceutical Category: Selected Other Non-recombinant Biologics

• To identify new business enterprises

• To receive news right in time

Get your personal copy every monday delivered by e-mail.

Das könnte Ihnen auch gefallen